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ABSTRACT
The development of breast and ovarian cancer is strongly connected to the 
inactivation of the BRCA1 and BRCA2 genes by different germline and somatic 
alterations, and their diagnosis has great significance in targeted tumor therapy, 
since recently approved PARP inhibitors show high efficiency in the treatment of 
BRCA-deficient tumors. This raises the need for new diagnostic methods that are 
capable of performing an integrative mutation analysis of the BRCA genes not only 
from germline DNA but also from formalin-fixed and paraffin-embedded (FFPE) 
tumor samples. Here we describe the development of such a methodology based on 
next-generation sequencing and a new bioinformatics software for data analysis. 
The diagnostic method was initially developed on an Illumina MiSeq NGS platform 
using germline-mutated stem cell lines and then adapted for the Ion Torrent PGM 
NGS platform as well. We also investigated the usability of NGS coverage data for 
the detection of copy number variations and exon deletions as a replacement of the 
conventional MLPA technique. Finally, we tested the developed workflow on FFPE 
samples from breast and ovarian cancer patients. Our method meets the sensitivity 
and specificity requirements for the genetic diagnosis of breast and ovarian cancers 
both from germline and FFPE samples.
INTRODUCTION
Next-generation sequencing (NGS) technologies 
have reshaped the image of molecular biology. These 
rapidly evolving technologies provide unprecedented scale 
and efficiency in DNA sequencing [1] with many potential 
advantages over traditional Sanger sequencing [2]. The 
introduction of benchtop NGS platforms opened the way 
for clinical diagnostic laboratories to incorporate this 
technology into their daily diagnostic routine. Performance 
comparison of different benchtop NGS platforms showed 
substantial differences between them in the quality of data 
and throughput capacity [3]. These differences have to be 
considered carefully when searching for the most suitable 
NGS platform to achieve specific diagnostic requirements 
and goals. Parallel to the spreading of different NGS 
methods, several target-enrichment technologies have 
also been introduced to isolate and prepare regions of 
the genome for NGS [4]. However, the efficiency and 
specificity limitations of different target-enrichment 
methods still represent a bottleneck for targeted NGS [5]. 
The diversity of sample preparation and NGS techniques 
used in research can offer a wide spectrum of solutions 
for DNA sequencing in the clinical practice. However, 
performance and quality criteria expected from NGS are 
markedly different in diagnostics and research. To meet 
regulatory requirements, clinical sequencing assays must 
be robust and reproducible, with well-defined sensitivity 
and specificity values [6] so that results can be applied 
with confidence when making treatment decisions [7].
Germline mutations of BRCA1 and BRCA2 
predispose to hereditary breast and ovarian cancer 
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syndrome (HBOCS) representing up to 10% of all breast 
cancers diagnosed annually [8]. Pathogenic mutations 
in these genes confer an estimated 40% to 85% lifetime 
risk of breast cancer and a 15% to 40% lifetime risk of 
ovarian cancer [9, 10]. Selection of women for genetic 
testing of BRCA1 and BRCA2 follows general guidelines 
based on their family history of cancer [11]. However, not 
all HBOCS patients fulfil these criteria mostly because of 
paternal inheritance of the susceptibility or the effect of a 
small family. The mutational status of these patients often 
remains unclarified [12, 13].
BRCA genes are also involved in the development 
of sporadic breast and ovarian tumors. Several studies 
have reported somatic BRCA1 and BRCA2 mutations in 
a considerable proportion of breast and ovarian cancers 
[14, 15]. The mutational status of the BRCA genes 
is important for selecting patients for personalized 
treatment, as patients carrying a germline or somatic 
BRCA mutation have shown to give a positive response 
to poly(ADP-ribose) polymerase-inhibitors (PARPi) [16, 
17]. Recently, several studies have pointed out that the 
miRNA expression pattern also has a significant effect on 
the progress and outcome of breast and ovarian cancer [18, 
19]. Assessing the molecular signature of tumor samples 
is thus a crucial step in the proper management of breast 
and ovarian cancer patients.
In clinical laboratories, the diagnostic sequencing 
of BRCA1 and BRCA2 is often performed by Sanger 
sequencing of individually amplified PCR products [20, 
21]. This method is suitable for the detection of single-
base substitutions, small insertions, and deletions. For the 
detection of copy number variations (CNV), alternative 
methods such as multiplex ligation-dependent probe 
amplification (MLPA) have to be used [22]. Due to the 
lack of mutational hotspots in the BRCA genes and their 
relatively large size, the traditional capillary sequencing-
based diagnostic process combined with MLPA analysis 
represents an expensive and time-consuming solution. 
In addition, tumor samples are usually heterogeneous 
containing normal and tumor cells in variable amounts, 
which often makes Sanger sequencing and MLPA analysis 
unreliable. The advent of different NGS and target-
enrichment methods offered the possibility to relocate the 
BRCA1 and BRCA2 mutation detection workflow onto 
these high-throughput platforms. Several NGS systems 
have already been evaluated using these two genes. 
The majority of the studies reporting BRCA diagnostic 
methods focus on the detection of germline mutations 
using blood samples, from which high-quality genomic 
DNA can be prepared [13,23–27]. However, the majority 
of tumor samples are formalin-fixed paraffin-embedded 
(FFPE) clinical specimens and thus DNA isolated from 
these samples has specific characteristics which often 
make the subsequent mutational analysis difficult: the 
amount of DNA isolated from FFPE samples is often 
limited, and the quality is poor due to deamination 
and cross-linking during formalin-fixation. Only a limited 
fraction of the available studies present some solution to 
somatic BRCA mutation detection from FFPE samples [28, 
29].
Given the diversity of sample types (blood, FFPE) 
and possible mutations (SNP, indels, CNVs) in BRCA 
analysis and due to the appearance of PARP inhibitors, 
there is a strong clinical demand for an integrative 
diagnostic solution to detect the various mechanisms of 
BRCA inactivation.
In this work, we present a multi-sided BRCA 
diagnostic method based on multiplex PCR amplification, 
next-generation sequencing, and computational variant 
identification that is versatile to face all the challenges 
mentioned above. Using previously validated sample 
pools, we optimized and validated the sequencing and 
mutation detection performance on the two most popular 
benchtop sequencing platforms: Illumina MiSeq and Ion 
Torrent PGM. We further demonstrate that the sample 
processing method used for the detection of germline 
mutations is also suitable for the identification of whole 
exon deletions and duplications. Most importantly, we 
show that the method performs well on FFPE samples 
of breast and ovarian tumors and is suitable for somatic 
mutation detection. Therefore, combining the multiplex 
PCR/NGS sequencing method with the appropriate NGS 
platform results in a complete integrative and robust 
diagnostic pipeline for BRCA1 and BRCA2 analysis.
RESULTS
A total of 24 DNA samples with known pathogenic 
germline mutations were used to calibrate the routine 
procedure, that is, multiplex PCR amplification, library 
preparation, and bioinformatics analysis parameters. To 
adequately address diagnostic issues, this sample set was 
composed of difficult cases, for example, insertions and/
or deletions of various sizes and mutations occurring in 
homopolymer regions of BRCA1 and BRCA2 (Table 1). 
Samples were pooled and sequenced together but remained 
readily identifiable using barcodes (indices) ligated to the 
amplicons during library preparation. The application 
of optimized experimental conditions resulted in a full 
coverage of the BRCA1 and BRCA2 regions of interest 
with uniform representation of each PCR amplicon in 
the coverage distribution (Figure 1). The average number 
of reads mapped per sample was 133,067 resulting in an 
average coverage of 689x.
During the optimization of the mutation detection 
algorithm, we paid special attention to large indels 
represented by two samples in the training set: an 11-bp 
deletion (GM14096) and a 40-bp-long deletion (NA14094). 
These indels were correctly mapped and identified by the 
in-house developed NGSeXplorer software (Supplementary 
Figure S1). As in the validation set we did not have the 
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possibility to include other samples with long indels, we 
evaluated the reproducibility of the identification of large 
indels by analyzing the above mentioned two samples 
in two independent sequencing runs. The coverage data 
and variant calling results of this reproducibility test are 
summarized in Supplementary Table S1.
After the initial optimization process, we blindly 
validated the diagnostic method on 20 samples each 
containing a unique pathogenic mutation (Table 2). 
At the same time, we compared the mutation detection 
performance of the two most popular NGS platforms: 
Illumina MiSeq and Ion Torrent PGM. Sequencing 
parameters, number of reads, and coverage values 
were evaluated for both sequencing platforms and 
are summarized in Table 3. The average read length 
was similar for both sequencing platforms and was 
mainly determined by the length of the DNA fragments 
generated after the restriction enzyme digestion of PCR 
products (Figure 2). Each manufacturer uses unique 
software implementations to generate base-quality score 
predictions, thus, direct comparison of these scores 
between different platforms is difficult, even taking into 
account that Ion Torrent PGM generally underestimates 
quality scores while Illumina MiSeq slightly overestimates 
them [3]. Based on the alignment of sequencing reads, we 
conclude that the substitution error rates produced by the 
two platforms are similar (0.29 and 0.23 substitutions 
per 100 bases for Illumina and Ion Torrent, respectively). 
Comparison of the frequency of insertions and deletions 
demonstrated that the Ion Torrent PGM reads had 1.27 
Table 1: BRCA1 and BRCA2 variants in the 24 Coriell Cell Line Reference Samples used as training set for the 
optimization of the workflow
Nr DNA ID Gene Mutation Exon
1 NA14090 BRCA1 c.66_67delAG 3
2 NA14638 c.213-11T>G 5
3 NA14684 c.797_798delTT 11
4 NA14094 c.1175_1214del40 11
5 NA14093 c.1204delG 11
6 NA13709 c.2068delA 11
7 NA13712 c.2155_2156insA 11
8 GM14096 c.3481_3491delGAAGATACTAG 11
9 NA13705 c.3756_3759delGTCT 11
10 NA14634 c.4065_4068delTCAA 11
11 NA13710 c.4327C>G 13
12 NA14637 c.4327C>T 13
13 NA13708 c.4752C>G 16
14 NA14095 c.5200delG 18
15 NA14092 c.5201T>C 18
16 NA13715 c.5326_5327insC 20
17 NA13714 c.5319_5320insC 21
18 NA14636 c.5621_5622insA 24
19 NA14623 BRCA2 c.125A>G 3
20 NA14624 c.5718_5719delCT 11
21 NA14170 c.5946delT 11
22 NA14639 c.6198_6199delTT 11
23 NA14622 c.6275_6276delTT 11
24 NA14626 c.9976A>T 27
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insertions and 0.67 deletions per 100 bases (Table 3), 
while in the case of Illumina MiSeq insertion and deletion 
events were nearly absent (0.01 and 0.04, respectively). 
The allelic ratio for mutation detection was adjusted to 
25% both for single nucleotide variation (SNV) and indel 
detection, with a minimum depth of coverage of 50x.
Illumina MiSeq mutation detection
Our in-house developed software (NGSeXplorer) 
correctly identified the known variants in all 20 
retrospective samples and correctly assigned 
homozygosity and heterozygosity, with no false-positive 
or false-negative variant predictions (Table 4). Illumina 
sequencing resulted in an experimental sensitivity [TP/
(TP + FN)] of 100% where TP is true-positive and FN 
is false-negative. In the absence of true-negative variants, 
specificity was estimated by using the false-positive 
(FP) rate FP/(FP + TP), resulting in 0%. Sensitivity and 
specificity values were calculated for the validation set of 
20 samples used in the performance comparison between 
the two platforms.
Ion Torrent PGM mutation detection
During the initial phase of mutation detection, 
all called variants (1148 variants per 20 samples) were 
retrieved from the Ion Torrent PGM sequence data set 
without applying any of the specific bioinformatic filters. 
After this, different filter thresholds were computed in order 
to minimize the number of false-positive calls without the 
introduction of false-negative results (Table 5). The filter 
thresholds were set as follows: depth test 5, insertion 
overrun 20%, deletion displacement 30%, HP percentage 
25%, and strand bias 35%. Modification of filter thresholds 
in order to reduce the number of false-positives would lead 
to the appearance of false-negative results.
From the 20 samples sequenced with Ion Torrent, 
in the case of 9 samples only the true pathogenic 
mutations remained after variant filtering. In the case of 
10 other samples, 1-4 false-positive pathogenic mutations 
remained in addition to the real one. In the case of the 
remaining one sample, the true pathogenic mutation was 
discarded by one of the variant filtering steps. This was a 
Cytosine to Adenine substitution (c.5645C>A) followed 
by a four-mer Adenine repeat. The mutation was filtered 
out by the Strand bias test because the average quality 
value of the surrounding bases (due to the homopolymer 
sequence) on the reverse strand was below threshold 
(Q10), hence, the majority of these reads were ignored 
during variant detection. In conclusion, Ion Torrent 
variant calling of pathogenic mutations resulted in an 
experimental sensitivity of 95.0% and a specificity of 
97.3% calculated as follows: [TN/(TN + FP)]. The overall 
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Figure 1: Distribution of coverage for each amplicon in BRCA1 a. and BRCA2 b. originating from Illumina MiSeq 
sequencing data. Each amplicon was surveyed at multiple reference points. Average was calculated from 24 samples. Error bars represent 
the minimum and maximum values of coverage in the respective amplicon.
Oncotarget61849www.impactjournals.com/oncotarget
accuracy [TP + TN/(TP + TN + FP + FN)] of the assay 
was 97.2%.
Copy number variation detection
To identify CNVs in the BRCA1 gene with our 
multiplex PCR/NGS sequencing method, we used 
Illumina MiSeq read counts as readout. We calculated 
the average DQs for all the 36 BRCA1 amplicons in four 
different groups representing the four multiplex reactions 
used for BRCA1 amplification. This DQ results from the 
comparison of normalized amplicon amounts between 
a test individual and control individuals as detailed in 
Materials and Methods. We presented the four DQs in 
a single scatter plot. The DQ values of the 36 BRCA1 
amplicons can be separated into three ranges of 0.5 
(range 0.55-0.63), 1.0 (range 0.81-1.2), and 1.5 (1.45), 
corresponding to the number of copies present in the 
individuals. Based on this segregation, we conclude that 
in one of the test samples, a deletion of exon 21 and 22 
has occurred, while in the other sample a duplication of 
exon 13 can be observed (Figure 3). The results are in 
concordance with those obtained with MLPA analysis.
FFPE sample analysis
The complementation of multiplex amplification 
with singleplex PCR reactions in case of FFPE samples 
ensured 100% coverage similarly to the germline samples. 
The mean depth of coverage was 2009x and 841x for the 
FFPE/matched normal samples with an average read 
number of 458,832 and 230,779, respectively. During the 
variant calling process, we identified pathogenic mutations 
in four of the ten tumor samples, all of them present in 
Table 2: List of BRCA mutant samples included in the validation set
Gene Mutation type Description
BRCA1 SNVs (polymorphisms c.181T>G
excluded) c.5251C>T
c.5074 G>C
Insertions/deletions c.843_846delCTCA
c1016_1017insA
c.1961delA
c.2985delTCTCA
c.3700_3704delGTAAA
c.3756_3759delGTCT
c.4065_4068delTCAA
c.5266dupC
Large rearrangements* del(ex21_22)
dup(ex13)
BRCA2 SNVs (polymorphisms c.5645C>A
excluded)
Insertions/deletions c.476-9_476-8insT
c.1813dupA
c.5073dupA
c.5351_5352insA
c.5946delT
c.7910-7914delCCTTT
c.9098_9099insA
c.9403delC
* The two large rearrangements in the case of BRCA1 are also included in this table.
Oncotarget61850www.impactjournals.com/oncotarget
BRCA1: a frame-shift insertion (c.5263_5264insC) and 
two nonsense mutation (c.628C>T and c.5251C>T). 
Mutational analysis of the matching normal samples 
revealed that three of the four identified mutations were 
germline, and only one tumor sample contained a somatic 
mutation (Table 6) that has not been recorded yet in 
the COSMIC database (c.628C>T; p. Q210*). All four 
pathogenic mutations were verified by Sanger sequencing. 
The newly identified somatic mutation (Q210*) was 
reported to COSMIC database (accession number: 41127). 
The tumor samples and their normal match also contained 
some common germline variants that are present in the 
majority of the population (Supplementary Table S2). In 
the case of the mutant and non-mutant FFPE DNA mixture, 
the mutant allele was detected in the first two admixtures 
(1/2 and 1/4) by the automated variant calling process. 
Table 3: Summary of read number, coverage, and mapping results of the two NGS platforms
Characteristics IlluminaMiSeq
Ion torrent
PGM
Flow cell/chip type Standard 316
Total no. of reads 14M 915k and 1.25M
Mean read length 99.3bp 99.24bp
Average quality of reads (Phred) 33.79 24.24
Average no. of reads/sample 247,749 99,774
%mapped reads 76% 88%
Coverage, mean [min, max] 1,262 [171, 3642] 439 [75, 1326]
% of target area with ≥ 50 fold coverage 99.93 99.68
% of insertions 0.01 1.27
% of deletions 0.04 0.67
% of mismatches 0.29 0.23
All values are average calculations from the 20 analyzed samples.
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Figure 2: Fragment size distribution of BRCA1-2 samples after the enzymatic fragmentation of multiplex PCR 
products.
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Table 4: Variant calling results from the validation set
Filtered variants
NGS Platform
Illumina MiSeq Ion torrent PGM
Total
False-positive 0 26
False-negative 0 16
True-positive 140 124
True-negative 982
Pathogenic
False-positive 0 16
False-negative 0 1
True-positive 20 19
True-negative 680
Table 5: Cumulative application of filters for Ion Torrent PGM data
Filters
Number of variants
Total Pathogenic
Total variants 1,148 715
Depth test 1,072 669
Insertion overrun 565 293
Deletion displacement 261 101
HP percentage 228 71
Strand bias 166 36
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Figure 3: The overall dosage plot for LGR analysis. Every dot is the average of the DQ of the amplicons of BRCA1 in two samples 
(diamond and square shaped dots).
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Visual inspection of filtered variants revealed the presence 
of the mutant allele also in the other two admixtures with 
frequencies below the variant detection threshold of 10% 
(Supplementary Table S3). The differences between the 
expected and observed allele frequencies are possibly due 
to the difference in the amount of amplifiable DNA in the 
FFPE samples used to generate the admixtures.
DISCUSSION
In this paper, we describe an integrative diagnostic 
solution for the analysis of the BRCA1 and BRCA2 genes. 
This method offers the possibility of detecting different 
mutation types such as point mutations, small deletions, 
and exon or allele losses both from germline and FFPE 
samples. The complete workflow is based on a multiplex 
PCR amplification and enzymatic fragmentation strategy 
to generate patient DNA library followed by NGS 
sequencing and data analysis. The use of restriction 
enzymes for NGS fragment library preparation is not a 
widespread method, but it has significant advantages when 
the copy number of the DNA to be sequenced is limited 
such as often in the case of FFPE-derived samples. For 
example, MseI restriction digestion has been successfully 
used for DNA fragmentation in single-cell whole-genome 
analyzing studies [30, 31]. Here we complemented the 
MseI-mediated fragmentation with two other restriction 
enzymes that recognize four-base motifs: Csp6I and 
FspBI. All three restriction enzymes generate TA 
overhangs at the 5’end of DNA fragments, which makes 
the subsequent ligation of adapter sequences easier.
For the optimization of the methodology, we used a 
training set of 24 DNA samples from stem cell lines with 
previously identified germline BRCA mutations. After 
adequate optimization of the multiplex PCR conditions 
and the library preparation process, all 24 samples were 
sequenced on an Illumina MiSeq platform. For NGS data 
analysis, initially we used platform-specific bioinformatics 
Table 6: List of the FFPE and matching normal samples of the ten ovarian cancer patients included in this test
Case nr. Tissue type Mutational status
1
Normal FFPE WT
Tumor FFPE-50% WT
2
Periph. blood WT
Tumor FFPE-30% WT
3
Periph. blood WT
Tumor FFPE-60% WT
4
Periph. blood WT
Tumor FFPE-80% WT
5
Periph. blood WT
Tumor FFPE-60% WT
6
Periph. blood WT
Tumor FFPE-60% WT
7
Periph. blood WT
Tumor FFPE-80% BRCA1: p.Q210*
8
Normal FFPE BRCA1: p.Ser1755?fs
Tumor FFPE-80% BRCA1: p.Ser1755?fs
9
Periph. blood BRCA1: p.Ser1755?fs
Tumor FFPE-30% BRCA1: p.Ser1755?fs
10
Periph. blood BRCA1: p.R1751*
Tumor FFPE-70% BRCA1: p.R1751*
Tumor cell percentage in FFPE samples was estimated visually by molecular pathologist. Lymphocyte DNA isolated from 
peripheral blood was originally used as a default reference normal DNA, however, in some cases this was not possible and 
thus was replaced by FFPE DNA from non-tumorous regions of the tissue-slide. Mutational status of the samples determined 
by NGS is also illustrated. Detailed list of mutations and neutral variants found in these 10 sample-pairs can be found in 
Supplementary Table S2.
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tools (Torrent Suite Software in the case of Ion Torrent 
and MiSeq Reporter software for Illumina). However, 
when it became clear that these tools do not fulfil all 
our expectations we developed our own bioinformatics 
pipeline, the NGSeXplorer. The software contains an 
accurate alignment module, a coverage generator, and a 
variant calling unit with several variant filtering algorithms 
for Ion Torrent PGM sequencing data. The software uses 
the Breast Cancer Information Core [32], the UMD, and 
the Ensembl.org databases for variant annotation. The 
most important factor for accurate mutation detection 
during NGS is the complete coverage of the target region 
as well as the optimal depth of coverage inside the 
target region. Coverage results of the training sample set 
clearly demonstrated that 100% of the target region was 
successfully covered by the PCR fragments amplified 
in multiplex setting. A major challenge in the multiplex 
PCR enrichment method is the uniform representation 
of different amplicons in the reactions and later in the 
coverage data. This was successfully overcome here by 
adjusting the primer concentrations and PCR conditions 
(Figure 1). Regarding the minimal depth of coverage 
for germline mutation detection, we took into account 
the range of 50-fold coverage, as suggested by several 
studies on BRCA analysis [7, 26]. In addition to fulfilling 
these conditions, all the pathogenic mutations in the 24 
training samples were accurately identified without any 
false-positive alterations, including the large indels that 
were identified in two independent sequencing runs 
(Supplementary Table S1).
After the initial optimization, a subsequent group 
of 20 samples were selected for the validation of the 
diagnostic process on Illumina MiSeq and Ion Torrent 
PGM. Different NGS platforms have already been 
evaluated using the BRCA1-2 genes as a model: some 
of these studies tested Ion Torrent PGM [26, 33], while 
others worked with Illumina HiSeq [7] or GS Junior 
from Roche 454 [34]. However, the direct comparison 
of these platforms using the same methodology in 
the context of BRCA1 and BRCA2 mutation detection 
performance is limited [27]. In our comparison of the 
two benchtop NGS platforms, Illumina MiSeq correctly 
identified all the pathogenic mutations in the 20 samples 
without the application of any of the variant filters. No 
false-positive mutations were identified. For Ion Torrent 
mutation detection, we used a set of variant filters 
developed to reduce sequencing error-derived false-
positive results (Table 5). The main disadvantage of Ion 
Torrent semiconductor sequencing relative to Illumina 
chemistry is associated with the inaccuracy of length 
determination in homopolymers [3]. These errors tend 
to increase in genomic regions where the occurrence of 
true polymorphisms is also higher [35] and, thus, it is 
analytically challenging to reduce these errors without 
compromising detection sensitivity [36]. In our case, the 
application of the variant filter set developed within the 
frames of NGSeXplorer led to a drastic reduction of false-
positive results illustrated by the specificity of 97.3%. 
Though, in one of the 20 samples a true pathogenic 
mutation was also discarded by one of the above 
mentioned filters resulting in an experimental sensitivity of 
95.0%. Despite the fact that this false-negative case can be 
traced back to special reasons, missing even a single true-
positive variant is unacceptable in a diagnostic setting. 
Visual inspection of the variant list before accepting the 
results of different filters could prevent the automatic 
rejection of true pathogenic mutations in the case of Ion 
Torrent sequencing (Figure 4).
A comprehensive diagnostic workflow for BRCA1 
and BRCA2 must include the ability of specific and 
accurate detection of large genomic rearrangements 
in these genes. It has already been demonstrated that 
multiplex PCR reactions can be used to determine the 
copy number of the amplified targets by calculating their 
DQ in the case of multiplex amplicon quantification 
(MAQ) [37] or quantitative multiplex PCR of short 
fluorescent fragments (QMPSF) [38]. A precondition for 
CNV detection using the multiplex PCR/NGS method is 
that the normalized read counts are stable over different 
samples [39]. For this reason, homogeneously prepared, 
high-quality DNA must be used with similar amplification 
kinetics [26]. Our multiplex PCR/NGS sequencing 
pipeline provides promising results regarding LGR 
detection since the CNVs present were correctly identified 
(Figure 3).
In the recent years, the ability to detect BRCA 
mutations in tumor samples of ovarian cancer patients has 
become increasingly important [40]. For these reasons, we 
tested the performance of our method on DNA samples 
isolated from FFPE tissue blocks of 10 ovarian cancer 
patients. Despite the fact that based on the results of 
other studies [15, 17, 29] the frequency of somatic BRCA 
mutations in ovarian cancer is relatively low (5-8%), 
their detection is important since patients with somatic 
BRCA pathogenic variants may benefit from treatment 
with PARPi, similarly to patients with germline BRCA 
mutations [41]. In addition to FFPE DNA, we also tested 
blood DNA since we share the suggestion made by others 
[28] that FFPE analysis should not be used as a substitute 
for comprehensive germline BRCA analysis. From the 
four pathogenic BRCA mutations identified in the FFPE 
samples, 3 were confirmed to be present in the germline 
as well. Consequently, one out of the ten analyzed tumor 
samples contained a somatic mutation not reported 
before. This highlights the importance of BRCA mutation 
detection from FFPE tumor samples [42]. The frequency 
of the identified somatic mutation was higher than 80% 
suggesting the loss of the second non-mutated allele (loss 
of heterozygosity (LOH)) in the tumor (but not the normal 
tissue). However, the experiment that we carried out with 
mutant and non-mutant FFPE DNA mixtures demonstrated 
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that our method is potentially able to detect mutations of 
low frequency (Supplementary Table S3).
To our knowledge, this is the first time the 
performance of an integrative NGS-based approach 
developed to perform comprehensive genetic testing of 
the BRCA genes has been evaluated on both germline and 
FFPE samples, simultaneously targeting a large spectrum 
of genetic alterations such as SNPs, indels, and LGRs. 
For germline mutations, the method was validated on 
the two most popular benchtop NGS platforms: Illumina 
MiSeq and Ion Torrent PGM. Our custom-designed 
NGS workflow for the genetic testing of germline BRCA 
mutations in combination with Illumina MiSeq sequencing 
meets the sensitivity and specificity requirements for the 
genetic diagnosis of HBOCS.
MATERIALS AND METHODS
Patients and DNA
DNA samples from cell lines with known 
deleterious variants in BRCA1 (n=18; Table 1) or BRCA2 
(n=6; Table 1) were purchased from the Coriell Mutant 
Cell Repository (Camden, NJ). These reference samples 
contained both pathogenic and non-pathogenic variants. 
We also obtained 22 blood samples (Table 2) from patients 
previously diagnosed with BRCA mutations validated by 
Sanger sequencing (Kecskemét Hospital, HU). For FFPE 
testing, we received DNA samples from the Department 
of Pathology, University of Szeged (HU): ten ovarian 
tumor samples with matching non-tumorous FFPE or 
lymphocyte DNA. All patient samples were collected 
with appropriate consents approved by the regulatory 
and ethical authorities. Genomic DNA was isolated 
using PureLink™ Genomic DNA Mini Kit (Invitrogen, 
Carlsbad, CA-USA) for the blood samples and High Pure 
FFPET DNA Isolation Kit (Roche, IN, USA) for the FFPE 
samples.
Multiplex PCR-based target amplification
The target region consisted of all coding exons of 
BRCA1 (NM_007294.2) and BRCA2 (NM_000059.3) as 
well as of the intronic sequences adjacent to each exon 
boundary. The adjacent intron length ranged between 10 
and 50 bp, except for the 3’ end of BRCA1 exon 9 and 
Sanger confirmation
Ion torrent PGM analysis of BRCA1 and BRCA2
Coverage: 50X
Variant frequency: 25%
Variant filter set
Filtered variants
Pathogenic mutation No pathogenic mutation
Visual inspection
Variant 
Rearrangement 
Tool
Figure 4: Strategy outline for mutation detection using Ion torrent PGM sequencing data.
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BRCA2 exon 9, 14, and 17, where it was shorter due to 
primer design parameter constrains. Although mutations 
further into intronic sequences have been reported, their 
frequency appears to be low, and their significance is 
often unclear [43]. Overall, target regions are expected to 
encompass the majority of pathogenic sequence changes 
in BRCA1 and BRCA2 including all intronic splice site 
mutations.
Primer design was performed using the freely 
available software Primer3 [44]. All primers were checked 
for primer-dimer interactions, both for self-dimers and 
cross-dimers, to prevent template-independent primer 
extension. The resulting primers were ordered from 
Integrated DNA Technologies (Coralville, Iowa, USA) 
and tested in simplex PCR reactions on 20 ng of genomic 
DNA using 10 μM per primer; the other parameters were 
the same as those of the multiplex PCR described below. 
The multiplex PCR-based strategy considerably reduced 
the number of amplification reactions: four multiplex 
reactions for BRCA1 and five multiplexes for BRCA2 
resulting in altogether 80 PCR fragments sized between 
186 and 812 base pairs. Multiplex PCR reactions for 
BRCA1 were performed in 35 μl volumes containing 1 × 
PCR buffer, 2.0 mM MgCl
2
, 2.5 mM dNTPs, 1.5 unit of 
Taq DNA polymerase (Thermo Scientific, Waltham, MA 
USA), and 20-50 ng of template DNA. Thermal cycler 
conditions were: 95°C for 2 min; 35 cycles of 95°C for 
20 s; 63.5°C for 30 s; 72°C for 50 s; and, finally, 2 min 
at 72°C. BRCA2 multiplexes were carried out in 25 μl 
volumes using 0.7 units Phusion High Fidelity Polymerase 
with 5xHF buffer and 10 mM dNTPs (Thermo Scientific). 
Thermal cycler conditions were: 98°C for 2 min; 35 
cycles of 98°C for 20 s; 63.5°C for 30 s; 72°C for 50 s; 
and, finally, 2 min at 72°C. In all multiplex reactions, 
primer concentrations were optimized and varied between 
0.05 pmol/μl and 0.2 pmol/μl final concentrations. PCR 
reactions were run on a 4% agarose gel for amplification 
quality control.
Library construction and sequencing
After successful amplification of all BRCA 
fragments, multiplex PCR products belonging to the 
same sample were pooled together (40% - BRCA1 and 
60% - BRCA2) and purified with a PCR cleanup kit 
(Geneaid, Taiwan). The large size-range of amplicons 
(200-800 bp) in the multiplex PCR reactions requires 
further fragmentation to overcome the limitation of 
sequencing length for the Illumina and IonTorrent NGS 
platforms. We decided to use restriction enzyme-based 
fragmentation, a highly efficient and reproducible way of 
DNA fragmentation, which also makes the upstream step 
of adaptor ligation easier. We searched among enzymes 
with 4-nucleotide recognition sites as, theoretically, these 
provide an ideal fragmentation pattern of 250 bp long 
DNA. We carried out in silico fragmentation of the target 
genes with different 4-mer recognition enzymes that 
generate sticky ends using Clone Manager 9 (Scientific 
& Educational Software, Denver, CO, USA). The tested 
enzymes were ranked based on the number and size of 
fragments generated and the compatibility of sticky ends 
generated after digestion. Finally, three enzymes fulfilled 
our criteria: MseI (NEB, Ipswich, MA), Csp6I, and FspBI 
(Thermo Scientific). These restriction enzymes have an 
optimal cleavage site distribution along the target genes 
to generate DNA fragments between the size ranges of 50 
and 300 base pairs (Figure 2). It was important to use more 
than one enzyme to ensure the presence of overlapping 
fragments similar to a random shearing with sonication. 
Most importantly, in case an enzyme site is inactivated 
by a point mutation the coverage of the respective 
region is ensured by the two neighboring enzyme sites. 
The possibility of two consecutive cleavage sites being 
inactivated was ignored. In most of the cases, additional 
enzyme sites were generated near the 5’ end of the primers 
to ensure the above mentioned optimal fragmentation 
conditions.
Restriction enzyme digestions were performed 
according to the manufacturer’s instructions and were 
purified using the Small DNA Fragments extraction Kit 
(Geneaid, Taiwan). Custom barcoded adaptor sequences 
specific for Illumina or Ion PGM were ligated to the 
fragmented samples using T4 DNA Ligase (Thermo 
Scientific). Nick translation was carried out with DNA 
Polymerase I (Thermo Scientific). Generated DNA 
fragment libraries were checked for adapter dimers and 
size range (~170-400 bp) using gel electrophoresis on a 
2% agarose gel. Samples were re-isolated from the gel 
with a DNA fragment extraction kit (Viogene, Taiwan). 
Fragment library quantification was carried out using the 
q-PCR-based quantification method (Kapa Biosystems) on 
LightCycler480 qPCR (Roche, Indianapolis, IN).
Illumina sequencing was carried out on the Illumina 
MiSeq system with Standard flow cell v2, following 
the manufacturer’s instructions. For IonTorrent PGM 
sequencing, we used the Ion PGM™ Template OT2 200 
Kit together with the Ion OneTouch™ 2 System (Thermo 
Fisher Scientific, Waltham, MA, USA). The generated 
ion sphere particles (ISP) were enriched using the ES 
module and were sequenced with an Ion PGM in a 200-
bp configuration on 316 chip (Thermo Fisher Scientific, 
Waltham, MA, USA).
Bioinformatic analyses
In addition to commercially available softwares, 
sequencing data were analyzed using the in-house 
developed NGSeXplorer bioinformatics software. A trial 
version of the software will be available at request from 
the authors.
The mapping algorithm of NGSeXplorer is 
composed of two distinct steps. In the first step, the 
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software identifies alignment start positions using 
Burrows–Wheeler Transformation (BWT) [45]. The start 
position is defined as a 20-nucleotide-long key sequence 
from both ends of the reads (the first and last 4 nucleotides 
of each read is excluded from the search process). This key 
sequence is then tested against the reference in forward 
and reverse directions using the preset error threshold 
values. In this case, the default value is 2, which means 
that the alignment is acceptable only if the maximum 
difference between the key and the reference sequence 
does not exceed 2. In the second step, the software 
performs an accurate local alignment from the previously 
identified starting positions using the Smith-Waterman 
(SW) algorithm [46]. In our case, the scoring matrix 
of the SW algorithm prefers mismatches over indels as 
follows: match 10, mismatch -8, indel -9. There are no 
open gap or extended gap penalties in the scoring matrix. 
Starting positions of reads that are in close proximity to 
each other (<5 nucleotides) are combined together, and 
a mapping process is carried out with them. The first 
possible mapping result is picked out, and a linear run 
time rearrangement algorithm is applied on it to optimize 
for gaps and mismatches. Each rearrangement is scored 
based on the number of matches/mismatches and the 
number and length of indels. Our default scoring matrix 
is based on resequencing known samples and empirically 
determining the values to reach the maximum correctly 
mapped reads. The scoring matrix is: 100 for match, 30 
for mismatch, 10 for deletion, and 1 for insertion; indels 
longer than 5 counted as match. In this way, the software 
can identify the best scored version of a read for the final 
alignment procedure. Since some primer positions occur 
within exons, alignments beginning at primer sites with 
sequences partially or exactly matching these primer 
sequences were soft-clipped. In other cases, primer 
sequences could hide real mutations during the variant 
calling process.
NGSeXplorer permits ready access to sample Binary 
alignment /Map format (BAM) and Variant Call Format 
(VCF) files. The VCF files are then further processed 
resulting in a preliminary classification of the observed 
variants: molecular classification (e.g. synonymous, 
missense, nonsense, frameshift) and clinical relevance 
based on locus-specific databases (BIC, UMD, Ensembl.
org). Variant assessment is then performed manually by the 
operator by rechecking the quality metrics of the individual 
variants and its concordance with the IGV data. If the 
variant identification is accurate, the variants are loaded 
into a traceable database where the following fields are 
automatically filled by the NGSeXplorer software interface: 
Gene, Exon, Nucleotide, Change, dbSNP rs#, HGVS 
designation, and VAF (Variant Allele Frequency). All called 
variants were identified according to the Human Genome 
Variation Society (HGVS) nomenclature (http://www.hgvs.
org/mutnomen) [47]. For variant calling from Ion Torrent 
sequencing data, we developed specific tests and a filter 
set with the purpose of reducing the high frequency of 
homopolymer sequencing errors specific to this platform:
Strand bias
The test filters out those variants that were detected 
only from one sequencing direction or whose frequency on 
the forward and reverse strands showed great difference 
(greater than 35%).
Depth test
Due to the enzymatic fragmentation of PCR 
fragments, sequencing of a nucleotide can start from 
several well-defined positions. The number of wild-type 
and mutant sequences arising from different start positions 
(different depths) is subjected to Mann–Whitney U test 
[48]. The test filters out those variants in which the pattern 
of depth distribution between wild-type and mutant reads 
shows a significant difference.
To further correct Ion Torrent homopolymer 
sequencing errors, we created a database from the 
sequencing data of 20 DNA samples that were considered 
wild-type for the BRCA1 and BRCA2 genes. The database 
contains the percentage values of insertion and deletion 
events for every base position, representing the basic 
error frequency of the platform for BRCA1 and BRCA2 
sequencing. Those positions where the indel frequency 
is lower than 10% (reliable error) are considered low-
error-frequency positions, and indel frequencies of newly 
sequenced samples measured for these positions are reliable 
and considered true variants if their frequency reaches or 
exceeds the indel detection limit of 25%. In high-error-
frequency positions, where the frequency of indel events 
is higher than 10%, the following filters have to be applied 
to distinguish between sequencing errors and true indels:
Insertion overrun
This filter presumes that if a true single nucleotide 
insertion takes place in a homopolymeric region of a 
sample, this insertion frequency will be higher than the 
value measured in the database for the same insertion. 
Moreover, in the above mentioned case the frequency of 
two nucleotide insertions will also be significantly higher 
than in the database.
Deletion displacement
If a true single nucleotide deletion event takes place 
in a homopolymer region, it will result in a shift of the 
ratio of plus and minus 1 nucleotide-long indels relative to 
the ratio measured in the database for the same position; 
thus, when the ratio of deletions increases and the ratio of 
insertions decreases in the same sequence position it refers 
to a true deletion event.
Homopolymer (HP) percentage
Based on our observations, the ratio of an indel 
measured in a homopolymer position often requires 
correction due to the high frequency of sequencing errors 
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in these regions. The correction we apply here is the 
difference between the frequencies of the opposite event 
in the database and in one particular sample, called HP-
opposite. The frequency of an insertion or deletion corrected 
with this value is called HP percentage. The filter uses a 
well-defined decision-algorithm for the correction process 
(Supplementary Figure S2 and Supplementary Table S4).
Variant rearrangement tool
This experimental tool finds all non-homopolymer, 
larger than one nucleotide indels with low allele frequency 
and realigns all sequences near the found indels to 
maximize the possible length of insertions and deletions.
The overall mutation detection workflow using 
the above mentioned filters and tools is summarized in 
Figure 4.
Large genomic rearrangements analysis
We evaluated the capacity of our multiplex PCR/
NGS sequencing method to detect large genomic 
rearrangements (LGRs) using coverage data from Illumina 
MiSeq sequencing. Coverage data of two test samples 
(Table 2) were compared after normalization to the average 
of three reference samples with normal copy number. The 
normalization calculation and the comparison procedure 
of count data were performed separately for each of the 
four BRCA1 multiplex PCRs as described previously 
[39]. Briefly, to determine the dosage quotient (DQ) of an 
amplicon in a given individual, the total absolute read count 
per specific multiplex was determined as the sum of the 
read counts for all amplicons of that specific multiplex. Per 
individual, the relative read count was determined for every 
amplicon as the ratio of the read count for that amplicon 
over the total absolute read count of the specific multiplex 
to which the amplicon belongs. The ratio of the relative read 
count of an amplicon of a test individual over the average 
relative read counts in the reference individuals results in 
the DQ for that amplicon in that individual. In short: DQitest 
= (RCi/RCall)test/(RC
i/RCall)ref with “RC”= read count; “i” = 
amplicon i; “all” = all amplicons; “test” = test individual; 
and “ref ” = reference individual. The copy number of the 
samples used in these calculations was initially determined 
using the MLPA BRCA1 kit (MRC Holland, Amsterdam) 
according to the manufacturer’s instructions.
FFPE sample analysis
We amplified the BRCA1 and BRCA2 genes from 
the ten FFPE tumor samples and matching normal tissue/
lymphocytes complementing the multiplex amplification 
with singleplex PCR reactions where it was necessary. We 
generated a fragment library and sequenced the samples 
on an Illumina MiSeq platform. For mutation detection, 
we used the NGSeXplorer with settings adapted for 
somatic variant calling: minimum coverage value of 100x 
and variant frequency threshold of 10%. We used mutant 
and non-mutant FFPE DNA mixtures in a serial dilution 
to demonstrate sensitivity limitations: one FFPE tumor 
sample with known BRCA pathogenic mutation (BRCA1: 
c.5263_5264insC) was mixed with non-mutant FFPE 
tumor DNA to make 1/2, 1/4, 1/8, and 1/16 admixtures.
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